Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PRECIGEN, INC.

Get SEC filing alerts via email and in your feed for PRECIGEN, INC.

PGEN

PRECIGEN, INC.

About PRECIGEN, INC.

Precigen is a biopharmaceutical company specializing in developing gene and cell therapies for immuno-oncology, autoimmune, and infectious diseases. Its core platforms include UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, focusing on precision medicine with targeted, controllable, and cost-effective treatments. The company advances therapies through research, clinical trials, and strategic partnerships, aiming to address unmet medical needs in cancer and infectious disease markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PRECIGEN, INC.

1
1
PRECIGEN, INC. Precigen Reports $23.3 Million Revenue in Q1 2026, Driven by Papzimeos Launch

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
PRECIGEN, INC. Precigen Reports 146.7% Revenue Growth and FDA Approval of Papzimeos in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
PRECIGEN, INC. Precigen Reports $2.9M Revenue Growth and $146.3M Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PRECIGEN, INC. Precigen Reports 19.4% Revenue Growth in Q2 2025, Despite $26.6M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PRECIGEN, INC. Precigen Reports $54.2 Million Net Loss in Q1 2025, Revenue Increases 25.9%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PRECIGEN, INC. Precigen Reports $126.2 Million Net Loss for Fiscal Year 2024, Focuses on PRGN-2012 Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PRECIGEN, INC. Precigen Reports Significant Financial Challenges, Net Loss Increases 21.1% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments